HCDR1 Therapy Has Positive Impact on Sjogren Syndrome as Well as Lupus, Its Maker XTL Reports
A therapy that XTL Biopharmaceuticals is developing for autoimmune diseases significantly reduced the expression of several cell signaling molecules called cytokines that play a role in the development of Sjögren’s syndrome (SS) associated with lupus, the company reported. The news came in a press release updating XTL’s efforts to develop hCDR1 for systemic…